Compare BNKK & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNKK | PDSB |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | 10 | 10 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 11.6M |
| IPO Year | 2020 | 2015 |
| Metric | BNKK | PDSB |
|---|---|---|
| Price | $1.31 | $0.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 110.6K | ★ 2.6M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,117,309.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 201.63 | N/A |
| 52 Week Low | $0.11 | $0.20 |
| 52 Week High | $7.19 | $1.55 |
| Indicator | BNKK | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 62.31 | 21.28 |
| Support Level | $1.25 | $0.20 |
| Resistance Level | $1.66 | $0.77 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 77.04 | 3.09 |
Bonk Inc provides over-the-counter products and consumer products in the United States. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It sells its products through direct customers, distributors, retailers, and e-commerce websites. The company generates revenue through various channels, its primary sales include nostingz suncare products which are sold through e-commerce platforms, licensing revenues from Photocil and sales of the Safety Shot Beverage. The company has two reportable segments: the dietary and energy beverage business and digital assets, consisting of investing for growth in the appreciation of the asset. It derives the majority of the revenue from the dietary and energy beverage segment.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.